Meeting
2023 ASCO Gastrointestinal Cancers Symposium
Clinical significance of D-amino acid profile for cancer detection in early stage and prediction of efficacy of nivolumab in gastric cancer.
Authors
Kai Tsugaru
Division of Gastroenterology and Hepatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan;
Kai Tsugaru , Tomohisa Sujino , Masashi Mita , Jumpei Sasabe , Akihiko Chida , Yosuke Harada , Kenro Hirata , Yasutaka Sukawa , Motohiko Kato , Hirofumi Kawakubo , Yasuo Hamamoto , Takanori Kanai
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Cancers of the Esophagus and Stomach and Other GI Cancers
Track
Esophageal and Gastric Cancer,Other GI Cancer
Sub Track
Tumor Biology, Biomarkers, and Pathology
Citation
J Clin Oncol 41, 2023 (suppl 4; abstr 453)
DOI
10.1200/JCO.2023.41.4_suppl.453
Abstract #
453
Poster Bd #
K19
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Impact of time-of-day on nivolumab monotherapy infusion in patients with metastatic gastric cancer.
First Author: Yasunobu Ishizuka
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Nivolumab (NIVO) + chemotherapy (chemo) vs chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC): 4 year (yr) follow-up of CheckMate 649.
First Author: Kohei Shitara
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Real-world (RW) effectiveness of nivolumab plus chemotherapy (NIVO+chemo) in patients (pts) with advanced or metastatic gastric carcinoma, gastroesophageal junction carcinoma, or esophageal adenocarcinoma (GC/GEJC/EAC).
First Author: Ian Chau
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Impact of adding nivolumab to first-line chemotherapy in patients with advanced gastric cancer.
First Author: Mai Utsumi